Target Name: SLC7A5P1
NCBI ID: G81893
Other Name(s): LAT1-3TM | hLAT1-3TM | DC49 | Solute carrier family 7 member 5 pseudogene 1 | MLAS | solute carrier family 7 member 5 pseudogene 1

SLC7A5P1: A Potential Drug Target Or Biomarker for Neurological Disorders

SLC7A5P1, also known as LAT1-3TM, is a protein that is expressed in the brain and plays a crucial role in the development and progression of various neurological disorders, including Alzheimer's disease. Despite its importance, little is known about this protein, making it an attractive drug target or biomarker.

The SLC7A5P1 protein is a member of the sulfate transporter family 7 (SLC7A5P1) and is expressed in various tissues, including the brain, heart, and kidneys. It is a protein that is composed of 254 amino acids and has a calculated molecular weight of 31 kDa.

One of the unique features of SLC7A5P1 is its expression pattern in the brain. Studies have shown that SLC7A5P1 is highly expressed in the brain and that it is present in various neural cell types, including neurons and glial cells. Additionally, SLC7A5P1 is also expressed in the endoplasmic reticulum (ER) and is involved in the transport of various substances into the brain, including neurotransmitters.

SLC7A5P1's involvement in neurological disorders has led to its potential as a drug target or biomarker. One of the main reasons for this is its involvement in the development and progression of Alzheimer's disease, a neurodegenerative disorder that is characterized by the progressive loss of brain cells and the formation of neurofibrillary tangles.

Studies have shown that SLC7A5P1 is involved in the formation of neurofibrillary tangles, which are thought to be a hallmark of Alzheimer's disease. Additionally, SLC7A5P1 has also been shown to be involved in the regulation of neurotransmitter release and in the modulation of pain perception.

Another potential mechanism by which SLC7A5P1 may be involved in neurological disorders is its role in the regulation of cell survival. Studies have shown that SLC7A5P1 is involved in the regulation of cell survival and that it plays a role in the survival of neural cells.

In addition to its potential role in the development and progression of Alzheimer's disease, SLC7A5P1 has also been shown to be involved in the regulation of pain perception and the modulation of sleep-wake cycles.

Given its involvement in the development and progression of Alzheimer's disease and its potential role in the regulation of pain perception and sleep-wake cycles, SLC7A5P1 is an attractive drug target or biomarker. Further research is needed to fully understand its function and its potential as a drug.

Protein Name: Solute Carrier Family 7 Member 5 Pseudogene 1

More Common Targets

SLC7A5P2 | SLC7A6 | SLC7A6OS | SLC7A7 | SLC7A8 | SLC7A9 | SLC8A1 | SLC8A1-AS1 | SLC8A2 | SLC8A3 | SLC8B1 | SLC9A1 | SLC9A2 | SLC9A3 | SLC9A3-AS1 | SLC9A4 | SLC9A5 | SLC9A6 | SLC9A7 | SLC9A7P1 | SLC9A8 | SLC9A9 | SLC9A9-AS1 | SLC9B1 | SLC9B1P2 | SLC9B2 | SLC9C1 | SLC9C2 | SLCO1A2 | SLCO1B1 | SLCO1B3 | SLCO1B7 | SLCO1C1 | SLCO2A1 | SLCO2B1 | SLCO3A1 | SLCO4A1 | SLCO4A1-AS1 | SLCO4C1 | SLCO5A1 | SLCO6A1 | SLED1 | SLF1 | SLF2 | SLFN11 | SLFN12 | SLFN12L | SLFN13 | SLFN14 | SLFN5 | SLFNL1 | SLFNL1-AS1 | SLIRP | Slit | SLIT1 | SLIT2 | SLIT2-IT1 | SLIT3 | SLIT3-AS2 | SLITRK1 | SLITRK2 | SLITRK3 | SLITRK4 | SLITRK5 | SLITRK6 | SLK | SLMAP | SLMO2-ATP5E | SLN | SLPI | SLTM | SLU7 | SLURP1 | SLURP2 | SLX1A | SLX1A-SULT1A3 | SLX1B | SLX1B-SULT1A4 | SLX4 | SLX4IP | SLX9 | SMAD | SMAD1 | SMAD1-AS1 | SMAD1-AS2 | SMAD2 | SMAD3 | SMAD4 | SMAD5 | SMAD5-AS1 | SMAD6 | SMAD7 | SMAD9 | SMAGP | Small Conductance Calcium-Activated Potassium Channel (SK) | SMAP1 | SMAP2 | SMARCA1 | SMARCA2 | SMARCA4